<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DIOVAN HCT
                         - hydrochlorothiazide and valsartan tablet, film coated </strong><br>PD-Rx Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use</span><span class="Bold"> </span><span class="Bold">Diovan</span> <span class="Bold">HCT</span><span class="Bold"> </span><span class="Bold">safely and effectively. </span><span class="Bold">See full prescribing information for</span><span class="Italics"> </span><span class="Bold">Diovan</span> <span class="Bold">HCT.</span><br><span class="Bold">Diovan</span><span class="Bold"> </span><span class="Bold">HCT (valsartan and hydrochlorothiazide USP) Tablets</span><br><span class="Bold">Initial U.S. Approval</span><span class="Bold">: </span>1998<br>
</div>
<div class="Warning"><div>
<h1 class="Warning">
<span class="Bold">WARNING:</span><span class="Bold"> </span><span class="Bold">AVOID </span><span class="Bold">USE IN PREGNANCY</span>
</h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold">When pregnancy</span><span class="Bold"> is detected</span><span class="Bold">, </span><span class="Bold">discontinue D</span><span class="Bold">iovan</span> <span class="Bold">HCT as soon as possible. </span><span class="Bold">D</span><span class="Bold">rugs that act directly on the </span><span class="Bold">renin</span>-<span class="Bold">angiotensin system can cause injury and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus. (5.1)</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Warnings and Precautions: Acute Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> (5.9)
		     
	2/2011 </p></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">
<span class="Bold">WARNING:</span><span class="Bold"> </span><span class="Bold">AVOID </span><span class="Bold">USE IN PREGNANCY</span>
</h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold">When pregnancy</span><span class="Bold"> is detected</span><span class="Bold">, </span><span class="Bold">discontinue D</span><span class="Bold">iovan</span> <span class="Bold">HCT as soon as possible. </span><span class="Bold">D</span><span class="Bold">rugs that act directly on the </span><span class="Bold">renin</span>-<span class="Bold">angiotensin system can cause injury and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus. (5.1)</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Diovan HCT is the combination tablet of valsartan (Diovan), an angiotensin II receptor blocker (ARB) and hydrochlorothiazide (HCTZ), a diuretic. Diovan HCT is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>:  (<a href="#section-1">1</a>)</p>
<ul class="Disc">
<li>In patients not adequately controlled with monotherapy (1)<br>
</li>
<li>As initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals (1)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Bold">General considerations:</span>  (<a href="#section-2">2</a>)</p>
<ul class="Disc">
<li>Maximum effects within 2 to 4 weeks after dose change (2.1)<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>: Not recommended for patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance ≤30 mL/min) (2.1, 5.8)<br>
</li>
<li>Diovan HCT may be administered with or without food.</li>
</ul>
<p class="Highlighta"><span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span>  (<a href="#section-2">2</a>)</p>
<ul class="Disc">
<li>
<span class="Bold">Add</span>-<span class="Bold">on </span><span class="Bold">t</span><span class="Bold">herapy</span> OR <span class="Bold">Initial therapy</span>: Initiate with 160/12.5 mg. Titrate upwards as needed to a maximum dose of 320/25 mg. One tablet daily (2.2, 2.4)<br>
</li>
<li>
<span class="Bold">Replacement therapy</span>: may be substituted for titrated components (2.3)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets (valsartan/HCTZ mg): 80/12.5, 160/12.5, 160/25, 320/12.5, 320/25  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">Anuria</span>; <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any sulfonamide-derived drugs (4)  (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Avoid fetal or neonatal exposure (5.1)<br>
</li>
<li>Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> with volume- and/or salt-depletion. Correct volume-depletion prior to administration. Not recommended as initial therapy in volume-depleted patients (2.4, 5.2)<br>
</li>
<li>Use with caution in patients with impaired hepatic (5.3) or renal (5.8) function<br>
</li>
<li>Observe for signs of fluid or <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> (5.7)<br>
</li>
<li>Thiazide diuretics may cause an exacerbation or activation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> (5.5)</li>
<li>Hydrochlorothiazide has been associated with acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>  (5.9)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common reasons for discontinuation of therapy with Diovan HCT were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. The only adverse experience that occurred in ≥2% of patients treated with Diovan HCT and at a higher incidence than placebo was <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span> (2.4% vs. 1.9%) (6.1)  (<a href="#section-6">6</a>)</p>
<p class="Highlighta"><span class="Bold"><br><br>To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span>  (<a href="#section-6">6</a>)</p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Hydrochlorothiazide</span><span class="Bold"> </span>(7):  (<a href="#section-7">7</a>)</p>
<ul class="Disc">
<li>Alcohol, barbiturates, narcotics: Potentiation of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span><br>
</li>
<li>Antidiabetic drugs: Dosage adjustment of antidiabetic may be required<br>
</li>
<li>Cholestyramine and colestipol: Reduced absorption of thiazides<br>
</li>
<li>Corticosteroids, Adrenocorticotrophic Hormone (ACTH): <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span><br>
</li>
<li>Lithium: Reduced renal clearance and high risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> when used with diuretics. Should not be given with diuretics.<br>
</li>
<li>Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Can reduce diuretic, natriuretic and antihypertensive effects of diuretics. Observe patient closely.</li>
</ul>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Nursing Mothers</span><span class="Bold">: </span>Nursing or drug should be discontinued (8.3)   (<a href="#section-8">8</a>)</p>
<p class="Highlighta">
		     
	  (<a href="#section-8">8</a>)</p>
<p class="Highlighta">
		     
	  (<a href="#section-8">8</a>)</p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 2/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">WARNING: </span><span class="Bold">AVOID </span><span class="Bold">USE IN PREGNANCY</span></a></h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1 </span><span class="Bold"> </span><span class="Bold">INDICATIONS AND USAGE</span></a></h1>
<h1><a href="#section-2" class="toc"><span class="Bold">2</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">D</span><span class="Bold">OSAGE AND ADMINISTRATION</span></a></h1>
<h2><a href="#section-2.1" class="toc"><span class="Bold">2.1</span><span class="Bold"> </span><span class="Bold">General Considerations</span></a></h2>
<h2><a href="#section-2.2" class="toc"><span class="Bold">2.2</span><span class="Bold"> </span><span class="Bold">Add</span>-<span class="Bold">On Therapy</span></a></h2>
<h2><a href="#section-2.3" class="toc"><span class="Bold">2.3</span><span class="Bold"> </span><span class="Bold">Replacement</span><span class="Bold"> Therapy</span></a></h2>
<h2><a href="#section-2.4" class="toc"><span class="Bold">2.4</span><span class="Bold"> </span><span class="Bold">Initial Therapy</span></a></h2>
<h1><a href="#section-3" class="toc"><span class="Bold">3 </span><span class="Bold"> </span><span class="Bold">DOSAGE FORMS AND STRENGTHS</span></a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4 </span><span class="Bold"> </span><span class="Bold">CONTRAINDICATIONS</span></a></h1>
<h1><a href="#section-5" class="toc"><span class="Bold">5 </span><span class="Bold"> </span><span class="Bold">WARNINGS AND PRECAUTIONS</span></a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold">5.1 </span><span class="Bold">Fetal/Neonatal Morbidity and Mortality</span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold">5.2 </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> in Volume</span>-<span class="Bold"> and/or Salt</span>-<span class="Bold">Depleted Patients</span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="Bold">5.3</span><span class="Bold"> </span><span class="Bold">I</span><span class="Bold">mpaired Hepatic Function</span></a></h2>
<h2><a href="#section-5.4" class="toc"><span class="Bold">5.4 </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reaction</span></span></a></h2>
<h2><a href="#section-5.5" class="toc"><span class="Bold">5.5 </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic Lupus Erythematosus</span></span></a></h2>
<h2><a href="#section-5.6" class="toc"><span class="Bold">5.6 </span><span class="Bold">Lithium Interaction</span></a></h2>
<h2><a href="#section-5.7" class="toc"><span class="Bold">5.7 </span><span class="Bold">Serum Electrolytes</span></a></h2>
<h2><a href="#section-5.8" class="toc"><span class="Bold">5.8 </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></span></a></h2>
<h2><a href="#section-5.9" class="toc"><span class="Bold">5.9 </span><span class="Bold">Acute <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">Myopia</span> and Secondary Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></span></a></h2>
<h1><a href="#section-6" class="toc"><span class="Bold">6 </span><span class="Bold"> </span><span class="Bold">ADVERSE REACTIONS</span></a></h1>
<h2><a href="#section-6.1" class="toc"><span class="Bold">6.1 </span><span class="Bold">Clinical </span><span class="Bold">Trials </span><span class="Bold">Experience</span></a></h2>
<h2><a href="#section-6.2" class="toc"><span class="Bold">6.2 </span><span class="Bold">Postmarketing Experience</span></a></h2>
<h1><a href="#section-7" class="toc"><span class="Bold">7 </span><span class="Bold"> </span><span class="Bold">DRUG INTERACTIONS</span></a></h1>
<h2><a href="#section-7.1" class="toc"><span class="Bold">7.3 </span><span class="Bold">Clinical Laboratory Test Findings</span></a></h2>
<h1><a href="#section-8" class="toc"><span class="Bold">8 </span><span class="Bold"> </span><span class="Bold">USE IN SPECIFIC POPULATIONS</span></a></h1>
<h2><a href="#section-8.1" class="toc"><span class="Bold">8.1 </span><span class="Bold">Pregnancy</span></a></h2>
<h2><a href="#section-8.2" class="toc"><span class="Bold">8.3 </span><span class="Bold">Nursing Mothers</span></a></h2>
<h2><a href="#section-8.3" class="toc"><span class="Bold">8.4</span><span class="Bold"> </span><span class="Bold">Pediatric Use</span></a></h2>
<h2><a href="#section-8.4" class="toc"><span class="Bold">8.5 </span><span class="Bold">Geriatric Use</span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">10</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">OVERDOSAGE</span></a></h1>
<h1><a href="#section-10" class="toc"><span class="Bold">11</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">DESCRIPTION</span></a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">12</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">CLINICAL PHARMACOLOGY</span></a></h1>
<h2><a href="#section-11.1" class="toc"><span class="Bold">12.1 </span><span class="Bold">Mechanism of Action</span></a></h2>
<h2><a href="#section-11.2" class="toc"><span class="Bold">12.2 </span><span class="Bold">Pharmacodynamics</span></a></h2>
<h2><a href="#section-11.3" class="toc"><span class="Bold">12.3 </span><span class="Bold">Pharmacokinetics</span></a></h2>
<h1><a href="#section-12" class="toc"><span class="Bold">13</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">NONCLINICAL TOXICOLOGY</span></a></h1>
<h2><a href="#section-12.1" class="toc"><span class="Bold">13.1 </span><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</span></a></h2>
<h2><a href="#section-12.2" class="toc"><span class="Bold">13.3</span><span class="Bold"> </span><span class="Bold">Developmental Toxicity Studies</span><span class="Bold"> </span></a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">14</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">CLINICAL STUDIES</span></a></h1>
<h2><a href="#section-13.1" class="toc"><span class="Bold">14.1 </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></a></h2>
<h2><a href="#section-13.2" class="toc"><span class="Bold">14.2 </span><span class="Bold">Initial </span><span class="Bold">T</span><span class="Bold">herapy</span><span class="Bold"> </span>-<span class="Bold"> </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></a></h2>
<h1><a href="#section-14" class="toc"><span class="Bold">16</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">HOW SUPPLIED/STORAGE AND HANDLING</span></a></h1>
<h1><a href="#section-15" class="toc"><span class="Bold">17 PATIENT COUNSELING INFORMATION</span></a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="section-1"></a><p></p>
<h1>
<span class="Bold">WARNING: </span><span class="Bold">AVOID </span><span class="Bold">USE IN PREGNANCY</span>
</h1>
<p class="First"><span class="Bold">When pregnancy is detected, </span><span class="Bold">discontinue </span><span class="Bold">Diovan</span> <span class="Bold">HCT</span><span class="Bold"><span class="Sup">®</span></span><span class="Bold"> as soon as possible.</span><span class="Bold"> Drugs that act directly on the renin</span>-<span class="Bold">angiotensin system can cause injury and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus</span><span class="Bold">. </span><span class="Bold">[</span><span class="Bold Italics">see </span><span class="Bold Italics">Warnings and Precautions </span><span class="Bold Italics">(5.1)</span><span class="Bold">]</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1>
<span class="Bold">1 </span><span class="Bold"> </span><span class="Bold">INDICATIONS AND USAGE</span>
</h1>
<p class="First">Diovan HCT (valsartan and hydrochlorothiazide, USP) is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
<p>Diovan HCT may be used in patients whose blood pressure is not adequately controlled on monotherapy.</p>
<p style="border-left:1px solid;"><span class="XmChange">Diovan HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">The choice of Diovan HCT as initial therapy for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> should be based on an assessment of potential benefits and risks.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Patients with stage 2 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> are at a relatively high risk for cardiovascular events (such as <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>), <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Data from the high dose multifactorial trial [<span class="Italics">see Clinical Studies</span> (14.1)] provides estimates of the probability of reaching a target blood pressure with Diovan HCT compared to valsartan or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Diovan HCT 320/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures.</span></p>
<a name="ia70984d8-ce46-4593-8423-594e4482a5d8"></a><table>
<col width="319">
<col width="319">
<tbody class="Headless">
<tr class="First">
<td class="Lrule">
<img alt="Figure 1: Probability of Achieving Systolic Blood Pressure &lt;140 mmHg at Week 8" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=85cdc21e-6dbc-4559-9c30-bc93fd21045c&amp;name=diovan-hct-01.jpg"><br><span class="Bold">Figure 1</span><span class="Bold">: </span><span class="Bold">Probability of Achieving Systolic Blood Pressure &lt;140 mmHg at Week </span><span class="Bold">8</span>
</td>
<td>
<img alt="Figure 2: Probability of Achieving Diastolic Blood Pressure &lt;90 mmHg at Week 8" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=85cdc21e-6dbc-4559-9c30-bc93fd21045c&amp;name=diovan-hct-02.jpg"><br><span class="Bold">Figure 2</span><span class="Bold">: </span><span class="Bold">Probability of Achieving Diastolic Blood Pressure</span><span class="Bold"> </span><span class="Bold">&lt;90 mmHg at Week </span><span class="Bold">8</span>
</td>
</tr>
<tr class="Last">
<td class="Lrule">
<img alt="Figure 3: Probability of Achieving Systolic Blood Pressure &lt;130 mmHg at Week 8" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=85cdc21e-6dbc-4559-9c30-bc93fd21045c&amp;name=diovan-hct-03.jpg"><br><span class="Bold">Figure 3</span><span class="Bold">: </span><span class="Bold">Probability of Achieving Systolic Blood Pressure &lt;130 mmHg at Week </span><span class="Bold">8</span><br>
</td>
<td>
<img alt="Figure 4: Probability of Achieving Diastolic Blood Pressure &lt;80 mmHg at Week 8" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=85cdc21e-6dbc-4559-9c30-bc93fd21045c&amp;name=diovan-hct-04.jpg"><br><span class="Bold">Figure 4</span><span class="Bold">: </span><span class="Bold">Probability of Achieving Diastolic Blood Pressure</span><span class="Bold"> </span><span class="Bold">&lt;80 mmHg at Week </span><span class="Bold">8</span>
</td>
</tr>
</tbody>
</table>
<p style="border-left:1px solid;"><span class="XmChange">For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 41% likelihood of achieving a goal of &lt;140 mmHg (systolic) and 60% likelihood of achieving &lt;90 mmHg (diastolic) on valsartan alone and the likelihood of achieving these goals on HCTZ alone is about 50% (systolic) or 57% (diastolic). The likelihood of achieving these goals on Diovan HCT rises to about 84% (systolic) or 80% (diastolic). The likelihood of achieving these goals on placebo is about 23% (systolic) or 36% (diastolic).</span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1>
<span class="Bold">2</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">D</span><span class="Bold">OSAGE AND ADMINISTRATION</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<h2>
<span class="Bold">2.1</span><span class="Bold"> </span><span class="Bold">General Considerations</span>
</h2>
<p class="First">The side effects of valsartan are generally rare and appear independent of dose. Those of hydrochlorothiazide are a mixture of dose-dependent (primarily <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>) and dose-independent phenomena (e.g., <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>), the former much more common than the latter [<span class="Italics">see Adverse Reactions (6)</span>].</p>
<p>Dose once-daily. Maximum antihypertensive effects are attained within 2 to 4 weeks after a change in dose.</p>
<p>Diovan HCT may be administered with or without food.</p>
<p>Diovan HCT may be administered with other antihypertensive agents.</p>
<p><span class="Italics">Elderly patients</span><span class="Italics">:</span><span class="Italics"> </span>No initial dosage adjustment is required for elderly patients.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span></span><span class="Italics">:</span> The usual regimens of therapy with Diovan HCT may be followed as long as the patient’s creatinine clearance is &gt;30 mL/min. In patients with more severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, loop diuretics are preferred to thiazides, so Diovan HCT is not recommended.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span></span><span class="Italics">:</span> Care should be exercised with dosing of Diovan HCT in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Start with a low dose and titrate slowly in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [<span class="Italics">s</span><span class="Italics">ee Warnings and Precautions (5.3)</span>]<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<h2>
<span class="Bold">2.2</span><span class="Bold"> </span><span class="Bold">Add</span>-<span class="Bold">On Therapy</span>
</h2>
<p class="First">A patient whose blood pressure is not adequately controlled with valsartan (or another ARB) alone or hydrochlorothiazide alone may be switched to combination therapy with Diovan HCT. </p>
<p>A patient who experiences dose-limiting adverse reactions on either component alone may be switched to Diovan HCT containing a lower dose of that component in combination with the other to achieve similar blood pressure reductions. The clinical response to Diovan HCT should be subsequently evaluated and if blood pressure remains uncontrolled after 3 to 4 weeks of therapy, the dose may be titrated up to a maximum of 320/25 mg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3"></a><p></p>
<h2>
<span class="Bold">2.3</span><span class="Bold"> </span><span class="Bold">Replacement</span><span class="Bold"> Therapy</span>
</h2>
<p class="First">Diovan HCT may be substituted for the titrated components.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4"></a><p></p>
<h2>
<span class="Bold">2.4</span><span class="Bold"> </span><span class="Bold">Initial Therapy</span>
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">The usual starting dose is Diovan HCT 160/12.5 mg once daily. The dosage can be increased after 1 to 2 weeks of therapy to a maximum of one 320/25 mg tablet once daily as needed to control blood pressure [<span class="Italics">see</span><span class="Italics"> Clinical Studies</span> (14.2)]. Diovan HCT is not recommended as initial therapy in patients with intravascular <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> [<span class="Italics">see</span><span class="Italics"> Warnings</span><span class="Italics"> and Precautions</span><span class="Italics"> </span>(5.2)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-3"></a><p></p>
<h1>
<span class="Bold">3 </span><span class="Bold"> </span><span class="Bold">DOSAGE FORMS AND STRENGTHS</span>
</h1>
<p class="First">80/12.5 mg tablets, imprinted CG/HGH (Side 1/Side 2)</p>
<p>160/12.5 mg tablets, imprinted CG/HHH</p>
<p>160/25 mg tablets, imprinted NVR/HXH</p>
<p>320/12.5 mg tablets, imprinted NVR/HIL</p>
<p>320/25 mg tablets, imprinted NVR/CTI</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>
<span class="Bold">4 </span><span class="Bold"> </span><span class="Bold">CONTRAINDICATIONS</span>
</h1>
<p class="First">Diovan HCT (valsartan and hydrochlorothiazide, USP) is contraindicated in patients who are hypersensitive to any component of this product.</p>
<p>Because of the hydrochlorothiazide component, this product is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other sulfonamide-derived drugs.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>
<span class="Bold">5 </span><span class="Bold"> </span><span class="Bold">WARNINGS AND PRECAUTIONS</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>
<span class="Bold">5.1 </span><span class="Bold">Fetal/Neonatal Morbidity and Mortality</span>
</h2>
<p class="First">Diovan HCT can cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus<span class="Italics">.</span></p>
<p>Drugs that act on the renin-angiotensin system can cause fetal and neonatal morbidity and mortality when used in pregnancy. In several dozen published cases, ACE inhibitor use during the second and third trimesters of pregnancy was associated with fetal and neonatal injury, including <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, neonatal skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, reversible or <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">irreversible renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> [<span class="Italics">see Use in Specific Populations (8.1)</span>].</p>
<p>Intrauterine exposure to thiazide diuretics is associated with fetal or <span class="product-label-link" type="condition" conceptid="195064" conceptname="Perinatal jaundice due to hepatocellular damage">neonatal jaundice</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and possibly other adverse reactions that have occurred in adults.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2>
<span class="Bold">5.2 </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> in Volume</span>-<span class="Bold"> and/or Salt</span>-<span class="Bold">Depleted Patients</span>
</h2>
<p class="First">Excessive reduction of blood pressure was rarely seen (0.7%) in patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncomplicated hypertension</span> treated with Diovan HCT in controlled trials. In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients receiving high doses of diuretics, symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> may occur. This condition should be corrected prior to administration of Diovan HCT, or the treatment should start under close medical supervision.</p>
<p>If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further treatment, which usually can be continued without difficulty once the blood pressure has stabilized.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3"></a><p></p>
<h2>
<span class="Bold">5.3</span><span class="Bold"> </span><span class="Bold">I</span><span class="Bold">mpaired Hepatic Function</span>
</h2>
<p class="First"><span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span>Thiazide diuretics should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span>.</p>
<p><span class="Bold">Valsartan</span><span class="Bold">: </span>As the majority of valsartan is eliminated in the bile, patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, including patients with biliary obstructive disorders, showed lower valsartan clearance (higher AUCs). Care should be exercised in administering Diovan (valsartan) to these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.4"></a><p></p>
<h2>
<span class="Bold">5.4 </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reaction</span></span>
</h2>
<p class="First"><span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> to hydrochlorothiazide may occur in patients with or without a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, but are more likely in patients with such a history.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.5"></a><p></p>
<h2>
<span class="Bold">5.5 </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic Lupus Erythematosus</span></span>
</h2>
<p class="First"><span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span>Thiazide diuretics have been reported to cause exacerbation or activation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.6"></a><p></p>
<h2>
<span class="Bold">5.6 </span><span class="Bold">Lithium Interaction</span>
</h2>
<p class="First"><span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span>Lithium generally should not be given with thiazides [<span class="Italics">see </span><span class="Italics">Drug Interactions</span><span class="Italics"> (7)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.7"></a><p></p>
<h2>
<span class="Bold">5.7 </span><span class="Bold">Serum Electrolytes</span>
</h2>
<p class="First"><span class="Bold">Valsartan – Hydrochlorothiazide</span><span class="Bold">: </span>In the controlled trials of various doses of the combination of valsartan and hydrochlorothiazide the incidence of hypertensive patients who developed <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (serum potassium &lt;3.5 mEq/L) was 3.0%; the incidence of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (serum potassium &gt;5.7 mEq/L) was 0.4%.</p>
<p>In controlled clinical trials of Diovan HCT (valsartan and hydrochlorothiazide, USP), the average change in serum potassium was near zero in subjects who received Diovan HCT 160/12.5 mg, 320/12.5 mg or 320/25 mg, but the average subject who received Diovan HCT 80/12.5 mg, 80/25 mg or 160/25 mg experienced a mild reduction in serum potassium.</p>
<p>In clinical trials, the opposite effects of valsartan (80, 160 or 320 mg) and hydrochlorothiazide (12.5 mg) on serum potassium approximately balanced each other in many patients. In other patients, one or the other effect may be dominant. Periodic determinations of serum electrolytes to detect possible <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> should be performed at appropriate intervals.</p>
<p><span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span>All patients receiving thiazide therapy should be observed for clinical signs of fluid or <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>: <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4289304" conceptname="Hypochloremic alkalosis">hypochloremic alkalosis</span>, and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. Serum and urine electrolyte determinations are particularly important when the patient is <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> excessively or receiving parenteral fluids. Warning signs or symptoms of fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, irrespective of cause, include dryness of mouth, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, muscular <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may develop, especially with brisk <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, when severe cirrhosis is present, or after prolonged therapy.</p>
<p>Interference with adequate oral electrolyte intake will also contribute to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may cause <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span> and may also sensitize or exaggerate the response of the heart to the toxic effects of digitalis (e.g., increased ventricular <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>).</p>
<p>Although any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (as in liver disease or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>), chloride replacement may be required in the treatment of <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">metabolic alkalosis</span>.</p>
<p>Dilutional <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> may occur in edematous patients in hot weather; appropriate therapy is water restriction, rather than administration of salt except in rare instances when the <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> is life-threatening. In actual <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">salt depletion</span>, appropriate replacement is the therapy of choice.</p>
<p><span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span> may occur or frank <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> may be precipitated in certain patients receiving thiazide therapy.</p>
<p>In diabetic patients, dosage adjustments of insulin or oral hypoglycemic agents may be required. <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> may occur with thiazide diuretics. Thus <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">latent diabetes</span> mellitus may become manifest during thiazide therapy.</p>
<p>The antihypertensive effects of the drug may be enhanced in the postsympathectomy patient.</p>
<p>If progressive <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> becomes evident, consider withholding or discontinuing diuretic therapy.</p>
<p>Thiazides have been shown to increase the urinary excretion of magnesium; this may result in <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>.</p>
<p>Thiazides may decrease urinary calcium excretion. Thiazides may cause intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Marked <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> may be evidence of hidden <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span>. Thiazides should be discontinued before carrying out tests for parathyroid function.</p>
<p>Increases in <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglyceride levels may be associated with thiazide diuretic therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.8"></a><p></p>
<h2>
<span class="Bold">5.8 </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></span>
</h2>
<p class="First"><span class="Bold">Valsartan</span><span class="Bold">: </span>As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists has been associated with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and/or progressive <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> and (rarely) with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Similar outcomes have been reported with Diovan<span class="Sup">®</span>.</p>
<p>In studies of ACE inhibitors in patients with unilateral or <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">bilateral renal artery stenosis</span>, increases in serum creatinine or blood urea nitrogen have been reported. In a 4-day trial of valsartan in 12 patients with <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">unilateral renal artery stenosis</span>, no significant increases in serum creatinine or blood urea nitrogen were observed. There has been no long-term use of valsartan in patients with unilateral or <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">bilateral renal artery stenosis</span>, but an effect similar to that seen with ACE inhibitors should be anticipated.</p>
<p><span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span>Thiazides should be used with caution in severe <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. In patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, thiazides may precipitate <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>. Cumulative effects of the drug may develop in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.9"></a><p></p>
<h2>
<span class="Bold">5.9 </span><span class="Bold">Acute <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">Myopia</span> and Secondary Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></span>
</h2>
<p class="First">Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">myopia</span> and acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.  Symptoms include acute onset of decreased visual acuity or <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span> and typically occur within hours to weeks of drug initiation.  Untreated acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> can lead to permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span>.  The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible.   Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled.  Risk factors for developing acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> may include a history of sulfonamide or <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">penicillin allergy</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1>
<span class="Bold">6 </span><span class="Bold"> </span><span class="Bold">ADVERSE REACTIONS</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>
<span class="Bold">6.1 </span><span class="Bold">Clinical </span><span class="Bold">Trials </span><span class="Bold">Experience</span>
</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reactions rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></p>
<p>Diovan HCT (valsartan and hydrochlorothiazide, USP) has been evaluated for safety in more than 5,700 patients, including over 990 treated for over 6 months, and over 370 for over 1 year. Adverse experiences have generally been mild and transient in nature and have only infrequently required discontinuation of therapy. The overall incidence of adverse reactions with Diovan HCT was comparable to placebo.</p>
<p>The overall frequency of adverse reactions was neither dose-related nor related to gender, age, or race. In controlled clinical trials, discontinuation of therapy due to side effects was required in 2.3% of valsartan-hydrochlorothiazide patients and 3.1% of placebo patients. The most common reasons for discontinuation of therapy with Diovan HCT were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</p>
<p>The only adverse reaction that occurred in controlled clinical trials in at least 2% of patients treated with Diovan HCT and at a higher incidence in valsartan-hydrochlorothiazide (n=4372) than placebo (n=262) patients was <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span> (2.4% vs. 1.9%).</p>
<p>Dose-related orthostatic effects were seen in fewer than 1% of patients. In individual trials, a dose-related increase in the incidence of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> was observed in patients treated with Diovan HCT.</p>
<p>Other adverse reactions that have been reported with valsartan-hydrochlorothiazide (&gt;0.2% of valsartan-hydrochlorothiazide patients in controlled clinical trials) without regard to causality, are listed below:</p>
<p><span class="Bold Italics">Cardiovascular</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span></p>
<p><span class="Bold Italics">Ear and </span><span class="Bold Italics">L</span><span class="Bold Italics">abyrinth</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span> and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
<p><span class="Bold Italics">Gastrointestinal</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
<p><span class="Bold Italics">General and </span><span class="Bold Italics">A</span><span class="Bold Italics">dministration </span><span class="Bold Italics">S</span><span class="Bold Italics">ite </span><span class="Bold Italics">C</span><span class="Bold Italics">onditions</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span></p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and </span><span class="Bold Italics">I</span><span class="Bold Italics">nfestations</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis acute</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span> and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span></p>
<p><span class="Bold Italics">Investigations</span><span class="Bold Italics">: </span>Blood urea increased</p>
<p><span class="Bold Italics">Musculoskeletal</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span></p>
<p><span class="Bold Italics">Nervous </span><span class="Bold Italics">S</span><span class="Bold Italics">ystem</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="4250121" conceptname="Dizziness on standing up">Dizziness postural</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span></p>
<p><span class="Bold Italics">Psychiatric</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span></p>
<p><span class="Bold Italics">Renal and </span><span class="Bold Italics">U</span><span class="Bold Italics">rinary</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Pollakiuria</span></p>
<p><span class="Bold Italics">Reproductive </span><span class="Bold Italics">S</span><span class="Bold Italics">ystem</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Erectile dysfunction</span></p>
<p><span class="Bold Italics">Respiratory, </span><span class="Bold Italics">T</span><span class="Bold Italics">horacic and </span><span class="Bold Italics">M</span><span class="Bold Italics">ediastinal</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4220211" conceptname="Congestion of nasal sinus">sinus congestion</span></p>
<p><span class="Bold Italics">Skin and </span><span class="Bold Italics">S</span><span class="Bold Italics">ubcutaneous </span><span class="Bold Italics">T</span><span class="Bold Italics">issue</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></p>
<p><span class="Bold Italics">Vascular</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></p>
<p>Other reported reactions seen less frequently in clinical trials included <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, decreased libido, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, sunburn, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, and <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>.</p>
<p><span class="Bold">Valsartan</span><span class="Bold">: </span>In trials in which valsartan was compared to an ACE inhibitor with or without placebo, the incidence of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">dry cough</span> was significantly greater in the ACE inhibitor group (7.9%) than in the groups who received valsartan (2.6%) or placebo (1.5%). In a 129-patient trial limited to patients who had had <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">dry cough</span> when they had previously received ACE inhibitors, the incidences of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> in patients who received valsartan, hydrochlorothiazide, or lisinopril were 20%, 19%, 69% respectively (p &lt;0.001).</p>
<p>Other reported reactions seen less frequently in clinical trials included <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
<p><span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span>Other adverse reactions that have been reported with hydrochlorothiazide, without regard to causality, are listed below:</p>
<p><span class="Bold Italics">Body As A Whole</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>;</p>
<p><span class="Bold Italics">Digestive</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (intrahepatic <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>), <span class="product-label-link" type="condition" conceptid="29056" conceptname="Sialoadenitis">sialadenitis</span>, cramping, <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span>;</p>
<p><span class="Bold Italics">Hematologic</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>;</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, necrotizing <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">angiitis</span> (<span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> and <span class="product-label-link" type="condition" conceptid="4182711" conceptname="Vasculitis of the skin">cutaneous vasculitis</span>), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> including <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>;</p>
<p><span class="Bold Italics">Metabolic</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>;</p>
<p><span class="Bold Italics">Musculoskeletal</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span>;</p>
<p><span class="Bold Italics">Nervous System/Psychiatric</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>;</p>
<p><span class="Bold Italics">Renal</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, renal dysfunction, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>;</p>
<p><span class="Bold Italics">Skin</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> including <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>;</p>
<p><span class="Bold Italics">Special Senses</span><span class="Bold Italics">: </span>transient <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4168789" conceptname="Xanthopsia">xanthopsia</span>.</p>
<p><span class="Bold">Initial </span><span class="Bold">T</span><span class="Bold">herapy </span>-<span class="Bold"> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></p>
<p>In a clinical study in patients with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (diastolic blood pressure ≥110 mmHg and systolic blood pressure ≥140 mmHg), the overall pattern of adverse reactions reported through six weeks of follow-up was similar in patients treated with Diovan HCT as initial therapy and in patients treated with valsartan as initial therapy. Comparing the groups treated with Diovan HCT (force-titrated to 320/25 mg) and valsartan (force-titrated to 320 mg), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> was observed in 6% and 2% of patients, respectively. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> was observed in 1% of those patients receiving Diovan HCT and 0% of patients receiving valsartan. There were no reported cases of <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> in either treatment group. Laboratory changes with Diovan HCT as initial therapy in patients with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> were similar to those reported with Diovan HCT in patients with less severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> [<span class="Italics">see </span><span class="Italics">Clinical Studies </span><span class="Italics">(14.2) and </span><span class="Italics">Drug Interactions</span><span class="Italics"> </span><span class="Italics">(7.3)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>
<span class="Bold">6.2 </span><span class="Bold">Postmarketing Experience</span>
</h2>
<p class="First">The following additional adverse reactions have been reported in valsartan or valsartan/hydrochlorothiazide postmarketing experience:
		     
	</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span><span class="Bold Italics">: </span>There are rare reports of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>;</p>
<p><span class="Bold Italics">Digestive</span><span class="Bold Italics">: </span>Elevated liver enzymes and very rare reports of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>;</p>
<p><span class="Bold Italics">Renal</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired renal function</span>;</p>
<p><span class="Bold Italics">Clinical Laboratory Tests</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span>;</p>
<p><span class="Bold Italics">Dermatologic</span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>;</p>
<p><span class="Bold Italics">Vascular:</span>  <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">Vasculitis</span>;</p>
<p><span class="Bold Italics">Nervous System: </span> <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>.</p>
<p>Rare cases of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported in patients receiving angiotensin II receptor blockers.</p>
<p>Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>
<span class="Bold">7 </span><span class="Bold"> </span><span class="Bold">DRUG INTERACTIONS</span>
</h1>
<p class="First"><span class="Bold">Valsartan</span><span class="Bold">: </span>No clinically significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> were observed when valsartan was coadministered with amlodipine, atenolol, cimetidine, digoxin, furosemide, glyburide, hydrochlorothiazide, or indomethacin. The valsartan-atenolol combination was more antihypertensive than either component, but it did not lower the heart rate more than atenolol alone.</p>
<p>Coadministration of valsartan and warfarin did not change the pharmacokinetics of valsartan or the time-course of the anticoagulant properties of warfarin.</p>
<p><span class="Italics">CYP</span><span class="Italics"> </span><span class="Italics">450 Interactions</span><span class="Italics">: In vitro </span>metabolism studies indicate that CYP 450 mediated drug interactions between valsartan and co-administered drugs are unlikely because of low extent of metabolism <span class="Italics">[see Pharmacokinetics (12.3)]</span>.</p>
<p><span class="Italics">Transporters:</span> The results from an <span class="Italics">in vitro</span> study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1 and the hepatic efflux transporter MRP2. Co-administration of inhibitors of the uptake transporter (rifampin, cyclosporine) or efflux transporter (ritonavir) may increase the systemic exposure to valsartan.</p>
<p><span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span>When administered concurrently, the following drugs may interact with thiazide diuretics:</p>
<p><span class="Italics">Alcohol, Barbiturates, or N</span><span class="Italics">arcotics</span> - Potentiation of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> may occur.</p>
<p><span class="Italics">Antidiabetic </span><span class="Italics">D</span><span class="Italics">rugs</span> (oral agents and insulin) - Dosage adjustment of the antidiabetic drug may be required.</p>
<p><span class="Italics">Other Antihypertensive D</span><span class="Italics">rugs</span> - Additive effect or potentiation.</p>
<p><span class="Italics">Cholestyramine and Colestipol R</span><span class="Italics">esins</span> - Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43% respectively.</p>
<p><span class="Italics">Corticosteroids, ACTH</span> - Intensified <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span>, particularly <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
<p><span class="Italics">Pressor A</span><span class="Italics">mines</span> (e.g., norepinephrine) - Possible decreased response to pressor amines but not sufficient to preclude their use.</p>
<p><span class="Italics">Skeletal Muscle Relaxants, N</span><span class="Italics">ondepolarizing</span> (e.g., tubocurarine) - Possible increased responsiveness to the muscle relaxant.</p>
<p><span class="Italics">Lithium</span> - Should not generally be given with diuretics. Diuretic agents reduce the renal clearance of lithium and add a high risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. Refer to the package insert for lithium preparations before use of such preparations with Diovan HCT.</p>
<p><span class="Italics">Non</span><span class="Italics">steroidal </span><span class="Italics">A</span><span class="Italics">nti</span><span class="Italics">-inflammatory Drugs</span> - In some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. Therefore, when Diovan HCT and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.</p>
<p><span class="Italics">Carbamazepine</span> – May lead to symptomatic <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.  </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2>
<span class="Bold">7.3 </span><span class="Bold">Clinical Laboratory Test Findings</span>
</h2>
<p class="First">In controlled clinical trials, clinically important changes in standard laboratory parameters were rarely associated with administration of Diovan HCT.</p>
<p><span class="Bold Italics">Creatinine</span><span class="Bold Italics">/Blood Urea N</span><span class="Bold Italics">itrogen (BUN)</span><span class="Bold Italics">: </span>Minor elevations in creatinine and BUN occurred in 2% and 15% respectively, of patients taking Diovan HCT and 0.4% and 6% respectively, given placebo in controlled clinical trials.</p>
<p><span class="Bold Italics">Hemoglobin and Hematocrit</span><span class="Bold Italics">: </span>Greater than 20% decreases in hemoglobin and hematocrit were observed in less than 0.1% of Diovan HCT patients, compared with 0.0% in placebo-treated patients.</p>
<p><span class="Bold Italics">Liver Function Tests</span><span class="Bold Italics">: </span>Occasional elevations (greater than 150%) of liver chemistries occurred in Diovan HCT-treated patients.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></span><span class="Bold Italics">: </span><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> was observed in 0.1% of patients treated with Diovan HCT and 0.4% of patients treated with placebo.</p>
<p><span class="Bold Italics">Serum Electrolytes</span><span class="Bold Italics">: </span>[<span class="Italics">see W</span><span class="Italics">arnings and Precautions</span><span class="Italics"> </span><span class="Italics">(</span><span class="Italics">5.7)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>
<span class="Bold">8 </span><span class="Bold"> </span><span class="Bold">USE IN SPECIFIC POPULATIONS</span>
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.1"></a><p></p>
<h2>
<span class="Bold">8.1 </span><span class="Bold">Pregnancy</span>
</h2>
<p class="First"><span class="Bold">Pregnancy Category D</span><span class="Bold"> </span>[<span class="Italics">see Warnings and Precautions (5.1)</span>]</p>
<p>Diovan HCT, like other drugs that act on the renin-angiotensin system, can cause fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> when used during the second or third trimester of pregnancy. Diovan HCT can cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p>
<p>Angiotensin II receptor antagonists, like valsartan, and angiotensin-converting enzyme (ACE) inhibitors exert similar effects on the renin-angiotensin system. In several dozen published cases, ACE inhibitor use during the second and third trimesters of pregnancy was associated with fetal and neonatal injury, including <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, neonatal skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, reversible or <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">irreversible renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">Oligohydramnios</span> was also reported, presumably from decreased fetal renal function. In this setting, <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> was associated with fetal limb <span class="product-label-link" type="condition" conceptid="4208264" conceptname="Muscle contracture">contractures</span>, craniofacial deformation, and hypoplastic lung development. <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">Prematurity</span>, <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">intrauterine growth retardation</span>, and <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span> were also reported, although it is not clear whether these occurrences were due to exposure to the drug. In a retrospective study, first trimester use of ACE inhibitors, a specific class of drugs acting on the renin-angiotensin system, was associated with a potential risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>.</p>
<p>When pregnancy occurs in a patient using Diovan HCT, the physician should discontinue Diovan HCT treatment as soon as possible. The physician should inform the patient about potential risks to the fetus based on the time of gestational exposure to Diovan HCT (first trimester only or later). If exposure occurs beyond the first trimester, an ultrasound examination should be done.</p>
<p>In rare cases when another antihypertensive agent can not be used to treat the pregnant patient, serial ultrasound examinations should be performed to assess the intraamniotic environment. Routine fetal testing with non-stress tests, biophysical profiles, and/or contraction stress tests may be appropriate based on gestational age and standards of care in the community. If <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> occurs in these situations, individualized decisions about continuing or discontinuing Diovan HCT treatment and about pregnancy management should be made by the patient, her physician, and experts in the management of high-risk pregnancy. Patients and physicians should be aware that <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> may not appear until after the fetus has sustained irreversible injury.</p>
<p>Infants with histories of <span class="Italics">in utero</span> exposure to Diovan HCT should be closely observed for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. If <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> occurs, these infants may require blood pressure and renal perfusion support. Exchange transfusion or dialysis may be required to reverse <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or support decreased renal function.</p>
<p>Healthcare professionals who prescribe drugs acting directly on the renin-angiotensin system should counsel women of childbearing potential about the risks of these agents during pregnancy. [<span class="Italics">see Nonclin</span><span class="Italics">i</span><span class="Italics">cal Toxicology (13)</span>]<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.2"></a><p></p>
<h2>
<span class="Bold">8.3 </span><span class="Bold">Nursing Mothers</span>
</h2>
<p class="First">It is not known whether valsartan is excreted in human milk. Valsartan was excreted into the milk of lactating rats; however, animal breast milk drug levels may not accurately reflect human breast milk levels. Hydrochlorothiazide is excreted in human breast milk. Because many drugs are excreted into human milk and because of the potential for adverse reactions in nursing infants from Diovan HCT, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.3"></a><p></p>
<h2>
<span class="Bold">8.4</span><span class="Bold"> </span><span class="Bold">Pediatric Use</span>
</h2>
<p class="First">Safety and effectiveness of Diovan HCT in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.4"></a><p></p>
<h2>
<span class="Bold">8.5 </span><span class="Bold">Geriatric Use</span>
</h2>
<p class="First">In the controlled clinical trials of Diovan HCT, 764 (17.5%) of patients treated with valsartan-hydrochlorothiazide were ≥65 years and 118 (2.7%) were ≥75 years. No overall difference in the efficacy or safety of valsartan-hydrochlorothiazide was observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>
<span class="Bold">10</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">OVERDOSAGE</span>
</h1>
<p class="First"><span class="Bold">Valsartan – Hydrochlorothiazide</span><span class="Bold">: </span>Limited data are available related to overdosage in humans. The most likely manifestations of overdosage would be <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> could occur from parasympathetic (vagal) stimulation. <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">Depressed level of consciousness</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span> and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> have been reported. If symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> should occur, supportive treatment should be instituted.</p>
<p>Valsartan is not removed from the plasma by dialysis.</p>
<p>The degree to which hydrochlorothiazide is removed by hemodialysis has not been established. The most common signs and symptoms observed in patients are those caused by <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span> (<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4016089" conceptname="Hypochloremia">hypochloremia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>) and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> resulting from excessive <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>. If digitalis has also been administered, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> may accentuate <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.</p>
<p>In rats and marmosets, single oral doses of valsartan up to 1524 and 762 mg/kg in combination with hydrochlorothiazide at doses up to 476 and 238 mg/kg, respectively, were very well tolerated without any treatment-related effects. These no adverse effect doses in rats and marmosets, respectively, represent 46.5 and 23 times the maximum recommended human dose (MRHD) of valsartan and 188 and 113 times the MRHD of hydrochlorothiazide on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 320 mg/day valsartan in combination with 25 mg/day hydrochlorothiazide and a 60-kg patient.)</p>
<p><span class="Bold">Valsartan</span><span class="Bold">: </span>Valsartan was without grossly observable adverse effects at single oral doses up to 2000 mg/kg in rats and up to 1000 mg/kg in marmosets, except for <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> in the rat and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> in the marmoset at the highest dose (60 and 31 times, respectively, the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis). (Calculations assume an oral dose of 320 mg/day and a 60-kg patient.)</p>
<p><span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span>The oral LD<span class="Sub">50</span> of hydrochlorothiazide is greater than 10 g/kg in both mice and rats, which represents 2027 and 4054 times, respectively, the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 25 mg/day and a 60-kg patient.)</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>
<span class="Bold">11</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">DESCRIPTION</span>
</h1>
<p class="First">Diovan HCT (valsartan and hydrochlorothiazide, USP) is a combination of valsartan, an orally active, specific angiotensin II receptor blocker (ARB) acting on the AT<span class="Sub">1</span> receptor subtype, and hydrochlorothiazide, a diuretic.</p>
<p>Valsartan, a nonpeptide molecule, is chemically described as <span class="Italics">N</span>-(1-oxopentyl)-<span class="Italics">N</span>-[[2′-(1<span class="Italics">H</span>-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-L-Valine. Its empirical formula is C<span class="Sub">24</span>H<span class="Sub">29</span>N<span class="Sub">5</span>O<span class="Sub">3</span>, its molecular weight is 435.5, and its structural formula is</p>
<p>
		     
	<img alt="Valsartan structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=85cdc21e-6dbc-4559-9c30-bc93fd21045c&amp;name=diovan-hct-05.jpg"></p>
<p>Valsartan is a white to practically white fine powder. It is soluble in ethanol and methanol and slightly soluble in water.</p>
<p>Hydrochlorothiazide USP is a white, or practically white, practically odorless, crystalline powder. It is slightly soluble in water; freely soluble in sodium hydroxide solution, in <span class="Italics">n</span>-butylamine, and in dimethylformamide; sparingly soluble in methanol; and insoluble in ether, in chloroform, and in dilute mineral acids. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro-2<span class="Italics">H</span>-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide.</p>
<p>Hydrochlorothiazide is a thiazide diuretic. Its empirical formula is C<span class="Sub">7</span>H<span class="Sub">8</span>ClN<span class="Sub">3</span>O<span class="Sub">4</span>S<span class="Sub">2</span>, its molecular weight is 297.73, and its structural formula is</p>
<p><img alt="Hydrochlorothiazide structural formula " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=85cdc21e-6dbc-4559-9c30-bc93fd21045c&amp;name=diovan-hct-06.jpg"></p>
<p>Diovan HCT tablets are formulated for oral administration to contain valsartan and hydrochlorothiazide, USP 80/12.5 mg, 160/12.5 mg, 160/25 mg, 320/12.5 mg and 320/25 mg. The inactive ingredients of the tablets are colloidal silicon dioxide, crospovidone, hydroxypropyl methylcellulose, iron oxides, magnesium stearate, microcrystalline cellulose, polyethylene glycol, talc, and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1>
<span class="Bold">12</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">CLINICAL PHARMACOLOGY</span>
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2>
<span class="Bold">12.1 </span><span class="Bold">Mechanism of Action</span>
</h2>
<p class="First">Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Valsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT<span class="Sub">1</span> receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensin II synthesis.</p>
<p>There is also an AT<span class="Sub">2</span> receptor found in many tissues, but AT<span class="Sub">2</span> is not known to be associated with cardiovascular homeostasis. Valsartan has much greater affinity (about 20,000-fold) for the AT<span class="Sub">1</span> receptor than for the AT<span class="Sub">2</span> receptor. The primary metabolite of valsartan is essentially inactive with an affinity for the AT<span class="Sub">1</span> receptor about one 200th that of valsartan itself.</p>
<p>Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I, is widely used in the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. ACE inhibitors also inhibit the degradation of bradykinin, a reaction also catalyzed by ACE. Because valsartan does not inhibit ACE (kininase II) it does not affect the response to bradykinin. Whether this difference has clinical relevance is not yet known. Valsartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.</p>
<p>Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of valsartan on blood pressure.</p>
<p>Hydrochlorothiazide is a thiazide diuretic. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium. The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.</p>
<p>The mechanism of the antihypertensive effect of thiazides is unknown.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-11.2"></a><p></p>
<h2>
<span class="Bold">12.2 </span><span class="Bold">Pharmacodynamics</span>
</h2>
<p class="First"><span class="Bold">Valsartan</span><span class="Bold">: </span>Valsartan inhibits the pressor effect of angiotensin II infusions. An oral dose of 80 mg inhibits the pressor effect by about 80% at peak with approximately 30% inhibition persisting for 24 hours. No information on the effect of larger doses is available.</p>
<p>Removal of the negative feedback of angiotensin II causes a 2- to 3-fold rise in plasma renin and consequent rise in angiotensin II plasma concentration in hypertensive patients. Minimal decreases in plasma aldosterone were observed after administration of valsartan; very little effect on serum potassium was observed.</p>
<p>In multiple-dose studies in hypertensive patients with stable <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> and patients with <span class="product-label-link" type="condition" conceptid="317895" conceptname="Renovascular hypertension">renovascular hypertension</span>, valsartan had no clinically significant effects on glomerular filtration rate, filtration fraction, creatinine clearance, or renal plasma flow.</p>
<p>In multiple-dose studies in hypertensive patients, valsartan had no notable effects on total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, fasting triglycerides, fasting serum glucose, or uric acid.</p>
<p><span class="Bold">Hydrochlorothiazide</span>: After oral administration of hydrochlorothiazide, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-11.3"></a><p></p>
<h2>
<span class="Bold">12.3 </span><span class="Bold">Pharmacokinetics</span>
</h2>
<p class="First"><span class="Bold">Valsartan</span><span class="Bold">: </span>Valsartan peak plasma concentration is reached 2 to 4 hours after dosing. Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours. Absolute bioavailability for the capsule formulation is about 25% (range 10%-35%). Food decreases the exposure (as measured by AUC) to valsartan by about 40% and peak plasma concentration (C<span class="Sub">max</span>) by about 50%. AUC and C<span class="Sub">max</span> values of valsartan increase approximately linearly with increasing dose over the clinical dosing range. Valsartan does not accumulate appreciably in plasma following repeated administration.</p>
<p><span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span>Thiazide diuretics are eliminated by the kidney, with a terminal half-life of 5-15 hours.</p>
<p><span class="Bold Italics">Geriatric</span><span class="Bold Italics">: </span>Exposure (measured by AUC) to valsartan is higher by 70% and the half-life is longer by 35% in the elderly than in the young. No dosage adjustment is necessary [<span class="Italics">see </span><span class="Italics">Dosage and Administration</span> <span class="Italics">(2</span>.<span class="Italics">1</span><span class="Italics">)</span>].</p>
<p><span class="Bold Italics">Gender</span><span class="Bold Italics">: </span>Pharmacokinetics of valsartan does not differ significantly between males and females.</p>
<p><span class="Bold Italics">Race</span><span class="Bold Italics">: </span>Pharmacokinetic differences due to race have not been studied.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></span><span class="Bold Italics">: </span>There is no apparent correlation between renal function (measured by creatinine clearance) and exposure (measured by AUC) to valsartan in patients with different degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Consequently, dose adjustment is not required in patients with mild-to-moderate renal dysfunction. No studies have been performed in patients with severe impairment of renal function (creatinine clearance &lt;10 mL/min). Valsartan is not removed from the plasma by hemodialysis. In the case of severe <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, exercise care with dosing of valsartan [<span class="Italics">see </span><span class="Italics">Dosage and Administration</span> <span class="Italics">(2</span>.<span class="Italics">1)</span>].</p>
<p>In a study of patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (mean creatinine clearance of 19 mL/min), the half-life of hydrochlorothiazide elimination was lengthened to 21 hours.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></span><span class="Bold Italics">: </span>On average, patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span> have twice the exposure (measured by AUC values) to valsartan of healthy volunteers (matched by age, sex, and weight). In general, no dosage adjustment is needed in patients with mild-to-moderate liver disease. Care should be exercised in patients with liver disease [<span class="Italics">see </span><span class="Italics">Dosage and Administration</span> <span class="Italics">(2</span>.<span class="Italics">1)</span>].</p>
<p><span class="Bold">Distribution</span></p>
<p><span class="Bold">Valsartan</span><span class="Bold">: </span>The steady state volume of distribution of valsartan after intravenous administration is small (17 L), indicating that valsartan does not distribute into tissues extensively. Valsartan is highly bound to serum proteins (95%), mainly serum albumin.</p>
<p><span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span>Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.</p>
<p><span class="Bold">Metabolism</span></p>
<p><span class="Bold">Valsartan</span><span class="Bold">: </span>The primary metabolite, accounting for about 9% of dose, is valeryl 4-hydroxy valsartan. In vitro metabolism studies involving recombinant CYP 450 enzymes indicated that the CYP 2C9 isoenzyme is responsible for the formation of valeryl-4-hydroxy valsartan. Valsartan does not inhibit CYP 450 isozymes at clinically relevant concentrations. CYP 450 mediated drug interaction between valsartan and co-administered drugs are unlikely because of the low extent of metabolism.</p>
<p><span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span>Is not metabolized.</p>
<p><span class="Bold">Excretion</span></p>
<p><span class="Bold">Valsartan</span><span class="Bold">: </span>Valsartan, when administered as an oral solution, is primarily recovered in feces (about 83% of dose) and urine (about 13% of dose). The recovery is mainly as unchanged drug, with only about 20% of dose recovered as metabolites.</p>
<p>Following intravenous administration, plasma clearance of valsartan is about 2 L/h and its renal clearance is 0.62 L/h (about 30% of total clearance).</p>
<p><span class="Bold">Hydrochlorothiazide</span>: Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. At least 61% of the oral dose is eliminated as unchanged drug within 24 hours. The elimination half-life is between 5.8 and 18.9 hours.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1>
<span class="Bold">13</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">NONCLINICAL TOXICOLOGY</span>
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2>
<span class="Bold">13.1 </span><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</span>
</h2>
<p class="First"><span class="Bold">Valsartan</span>-<span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span>No carcinogenicity, mutagenicity or fertility studies have been conducted with the combination of valsartan and hydrochlorothiazide. However, these studies have been conducted for valsartan as well as hydrochlorothiazide alone. Based on the preclinical safety and human pharmacokinetic studies, there is no indication of any adverse interaction between valsartan and hydrochlorothiazide.</p>
<p><span class="Bold">Valsartan</span><span class="Bold">: </span>There was no evidence of carcinogenicity when valsartan was administered in the diet to mice and rats for up to 2 years at doses up to 160 and 200 mg/kg/day, respectively. These doses in mice and rats are about 2.6 and 6 times, respectively, the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 320 mg/day and a 60-kg patient.)</p>
<p>Mutagenicity assays did not reveal any valsartan-related effects at either the gene or chromosome level. These assays included bacterial mutagenicity tests with <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span><span class="Italics"> </span>(Ames) and <span class="Italics">E. coli</span>; a gene mutation test with Chinese hamster V79 cells; a cytogenetic test with Chinese hamster ovary cells; and a rat micronucleus test.</p>
<p>Valsartan had no adverse effects on the reproductive performance of male or female rats at oral doses up to 200 mg/kg/day. This dose is about 6 times the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 320 mg/day and a 60-kg patient.)</p>
<p><span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span>Two-year feeding studies in mice and rats conducted under the auspices of the National Toxicology Program (NTP) uncovered no evidence of a carcinogenic potential of hydrochlorothiazide in female mice (at doses of up to approximately 600 mg/kg/day) or in male and female rats (at doses of up to approximately 100 mg/kg/day). The NTP, however, found equivocal evidence for hepatocarcinogenicity in male mice.</p>
<p>Hydrochlorothiazide was not genotoxic in vitro in the Ames mutagenicity assay of <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> Typhimurium <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> TA 98, TA 100, TA 1535, TA 1537, and TA 1538 and in the Chinese Hamster Ovary (CHO) test for chromosomal aberrations, or in vivo in assays using mouse germinal cell chromosomes, Chinese hamster bone marrow chromosomes, and the Drosophila sex-linked recessive lethal trait gene. Positive test results were obtained only in the in vitro CHO Sister Chromatid Exchange (clastogenicity) and in the Mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> Cell (mutagenicity) assays, using concentrations of hydrochlorothiazide from 43 to 1300 mcgm/mL, and in the Aspergillus Nidulans non-disjunction assay at an unspecified concentration.</p>
<p>Hydrochlorothiazide had no adverse effects on the fertility of mice and rats of either sex in studies wherein these species were exposed, via their diet, to doses of up to 100 and 4 mg/kg, respectively, prior to mating and throughout gestation. These doses of hydrochlorothiazide in mice and rats represent 19 and 1.5 times, respectively, the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 25 mg/day and a 60-kg patient.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2"></a><p></p>
<h2>
<span class="Bold">13.3</span><span class="Bold"> </span><span class="Bold">Developmental Toxicity Studies</span><span class="Bold"> </span>
</h2>
<p class="First"><span class="Bold">Valsartan-Hydrochlorothiazide</span><span class="Bold">: </span>There was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in mice, rats, or rabbits treated orally with valsartan at doses up to 600, 100 and 10 mg/kg/day, respectively, in combination with hydrochlorothiazide at doses up to 188, 31 and 3 mg/kg/day. These non-teratogenic doses in mice, rats and rabbits, respectively, represent 9, 3.5 and 0.5 times the maximum recommended human dose (MRHD) of valsartan and 38, 13 and 2 times the MRHD of hydrochlorothiazide on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 320 mg/day valsartan in combination with 25 mg/day hydrochlorothiazide and a 60-kg patient.)</p>
<p>Fetotoxicity was observed in association with maternal toxicity in rats and rabbits at valsartan doses of ≥200 and 10 mg/kg/day, respectively, in combination with hydrochlorothiazide doses of ≥63 and 3 mg/kg/day. Fetotoxicity in rats was considered to be related to decreased fetal weights and included fetal variations of sternebrae, vertebrae, ribs and/or renal papillae. Fetotoxicity in rabbits included increased numbers of late resorptions with resultant increases in total resorptions, postimplantation losses and decreased number of live fetuses. The no observed adverse effect doses in mice, rats and rabbits for valsartan were 600, 100 and 3 mg/kg/day, respectively, in combination with hydrochlorothiazide doses of 188, 31 and 1 mg/kg/day. These no adverse effect doses in mice, rats and rabbits, respectively, represent 9, 3 and 0.18 times the MRHD of valsartan and 38, 13 and 0.5 times the MRHD of hydrochlorothiazide on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 320 mg/day valsartan in combination with 25 mg/day hydrochlorothiazide and a 60-kg patient.)</p>
<p><span class="Bold">Valsartan</span><span class="Bold">: </span>No teratogenic effects were observed when valsartan was administered to pregnant mice and rats at oral doses up to 600 mg/kg/day and to pregnant rabbits at oral doses up to 10 mg/kg/day. However, significant decreases in fetal weight, pup birth weight, pup survival rate, and slight delays in developmental milestones were observed in studies in which parental rats were treated with valsartan at oral, maternally toxic (reduction in body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and food consumption) doses of 600 mg/kg/day during organogenesis or late gestation and lactation. In rabbits, fetotoxicity (i.e., resorptions, litter loss, abortions, and low body weight) associated with maternal toxicity (mortality) was observed at doses of 5 and 10 mg/kg/day. The no observed adverse effect doses of 600, 200 and 2 mg/kg/day in mice, rats and rabbits represent 9, 6 and 0.1 times, respectively, the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 320 mg/day and a 60-kg patient.)</p>
<p><span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span>Under the auspices of the National Toxicology Program, pregnant mice and rats that received hydrochlorothiazide via gavage at doses up to 3000 and 1000 mg/kg/day, respectively, on gestation days 6 through 15 showed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. These doses of hydrochlorothiazide in mice and rats represent 608 and 405 times, respectively, the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis. (Calculations assume an oral dose of 25 mg/day and a 60-kg patient.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1>
<span class="Bold">14</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">CLINICAL STUDIES</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<h2>
<span class="Bold">14.1 </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span>
</h2>
<p class="First"><span class="Bold">Valsartan</span>-<span class="Bold">Hydrochlorothiazide</span><span class="Bold">: </span>In controlled clinical trials including over 7600 patients, 4372 patients were exposed to valsartan (80, 160 and 320 mg) and concomitant hydrochlorothiazide (12.5 and 25 mg). Two factorial trials compared various combinations of 80/12.5 mg, 80/25 mg, 160/12.5 mg, 160/25 mg, 320/12.5 mg and 320/25 mg with their respective components and placebo. The combination of valsartan and hydrochlorothiazide resulted in additive placebo-adjusted decreases in systolic and diastolic blood pressure at trough of 14-21/8-11 mmHg at 80/12.5 mg to 320/25 mg, compared to 7-10/4-5 mmHg for valsartan 80 mg to 320 mg and 5-11/2-5 mmHg for hydrochlorothiazide 12.5 mg to 25 mg, alone.</p>
<p>Three other controlled trials investigated the addition of hydrochlorothiazide to patients who did not respond adequately to valsartan 80 mg to valsartan 320 mg, resulted in the additional lowering of systolic and diastolic blood pressure by approximately 4-12/2-5 mmHg.</p>
<p>The maximal antihypertensive effect was attained 4 weeks after the initiation of therapy, the first time point at which blood pressure was measured in these trials.</p>
<p>In long-term follow-up studies (without placebo control) the effect of the combination of valsartan and hydrochlorothiazide appeared to be maintained for up to two years. The antihypertensive effect is independent of age or gender. The overall response to the combination was similar for Black and non-Black patients.</p>
<p>There was essentially no change in heart rate in patients treated with the combination of valsartan and hydrochlorothiazide in controlled trials.</p>
<p><span class="Bold">Valsartan</span><span class="Bold">: </span>The antihypertensive effects of valsartan were demonstrated principally in 7 placebo-controlled, 4- to 12-week trials (one in patients over 65) of dosages from 10 to 320 mg/day in patients with baseline diastolic blood pressures of 95-115. The studies allowed comparison of once-daily and twice-daily regimens of 160 mg/day; comparison of peak and trough effects; comparison (in pooled data) of response by gender, age, and race; and evaluation of incremental effects of hydrochlorothiazide.</p>
<p>Administration of valsartan to patients with <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> results in a significant reduction of sitting, supine, and standing systolic and diastolic blood pressure, usually with little or no orthostatic change.</p>
<p>In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs at approximately 2 hours, and maximum reduction of blood pressure is achieved within 6 hours. The antihypertensive effect persists for 24 hours after dosing, but there is a decrease from peak effect at lower doses (40 mg) presumably reflecting loss of inhibition of angiotensin II. At higher doses, however (160 mg), there is little difference in peak and trough effect. During repeated dosing, the reduction in blood pressure with any dose is substantially present within 2 weeks, and maximal reduction is generally attained after 4 weeks. In long-term follow-up studies (without placebo control) the effect of valsartan appeared to be maintained for up to two years. The antihypertensive effect is independent of age, gender or race. The latter finding regarding race is based on pooled data and should be viewed with caution, because antihypertensive drugs that affect the renin-angiotensin system (that is, ACE inhibitors and angiotensin II blockers) have generally been found to be less effective in low-renin hypertensives (frequently Blacks) than in high-renin hypertensives (frequently Whites). In pooled, randomized, controlled trials of Diovan that included a total of 140 Blacks and 830 Whites, valsartan and an ACE-inhibitor control were generally at least as effective in Blacks as Whites. The explanation for this difference from previous findings is unclear.</p>
<p>Abrupt withdrawal of valsartan has not been associated with a rapid increase in blood pressure.</p>
<p>The 7 studies of valsartan monotherapy included over 2000 patients randomized to various doses of valsartan and about 800 patients randomized to placebo. Doses below 80 mg were not consistently distinguished from those of placebo at trough, but doses of 80, 160 and 320 mg produced dose-related decreases in systolic and diastolic blood pressure, with the difference from placebo of approximately 6-9/3-5 mmHg at 80-160 mg and 9/6 mmHg at 320 mg.</p>
<p>Patients with an inadequate response to 80 mg once daily were titrated to either 160 mg once daily or 80 mg twice daily, which resulted in a comparable response in both groups.</p>
<p>In another 4-week study, 1876 patients randomized to valsartan 320 mg once daily had an incremental blood pressure reduction 3/1 mmHg lower than did 1900 patients randomized to valsartan 160 mg once daily.</p>
<p>In controlled trials, the antihypertensive effect of once daily valsartan 80 mg was similar to that of once daily enalapril 20 mg or once daily lisinopril 10 mg.</p>
<p>There was essentially no change in heart rate in valsartan-treated patients in controlled trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2"></a><p></p>
<h2>
<span class="Bold">14.2 </span><span class="Bold">Initial </span><span class="Bold">T</span><span class="Bold">herapy</span><span class="Bold"> </span>-<span class="Bold"> </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span>
</h2>
<p class="First">The safety and efficacy of Diovan HCT as initial therapy for patients with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (defined as a sitting diastolic blood pressure ≥110 mmHg and systolic blood pressure ≥140 mmHg off all antihypertensive therapy) was studied in a 6-week multicenter, randomized, double-blind study. Patients were randomized to either Diovan HCT (valsartan and hydrochlorothiazide 160/12.5 mg once daily) or to valsartan (160 mg once daily) and followed for blood pressure response. Patients were force-titrated at 2-week intervals. Patients on combination therapy were subsequently titrated to 160/25 mg followed by 320/25 mg valsartan/hydrochlorothiazide. Patients on monotherapy were subsequently titrated to 320 mg valsartan followed by a titration to 320 mg valsartan to maintain the blind. </p>
<p>The study randomized 608 patients, including 261 (43%) females, 147 (24%) Blacks, and 75 (12%) ≥65 years of age. The mean blood pressure at baseline for the total population was 168/112 mmHg. The mean age was 52 years. After 4 weeks of therapy, reductions in systolic and diastolic blood pressure were 9/5 mmHg greater in the group treated with Diovan HCT compared to valsartan. Similar trends were seen when the patients were grouped according to gender, race or age. </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>
<span class="Bold">16</span><span class="Bold"> </span><span class="Bold"> </span><span class="Bold">HOW SUPPLIED/STORAGE AND HANDLING</span>
</h1>
<p class="First">Diovan HCT (valsartan and hydrochlorothiazide, USP) is available as non-scored tablets containing valsartan/hydrochlorothiazide 80/12.5 mg, 160/12.5 mg, 160/25 mg, 320/12.5 mg and 320/25 mg. Strengths are available as follows.</p>
<p><span class="Bold">80/12.5</span> <span class="Bold">mg Tablet</span> - Light orange, ovaloid with slightly convex faces debossed CG on one side and HGH on the other side.</p>
<p>
		     
	Bottles of 90
		     
	NDC 0078-0314-34</p>
<p>
		     
	Bottles of 14,000
		     
	NDC 0078-0314-33</p>
<p>
		     
	Unit Dose (<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack)
		     
	NDC 0078-0314-06</p>
<p>
		     
	   Box of 100 (strips of 10)</p>
<p><span class="Bold">160/12.5</span> <span class="Bold">mg Tablet</span> - Dark red, ovaloid with slightly convex faces debossed CG on one side and HHH on the other side.</p>
<p>
		     
	Bottles of 90
		     
	NDC 0078-0315-34</p>
<p>
		     
	Bottles of 7,000
		     
	NDC 0078-0315-17</p>
<p>
		     
	Unit Dose (<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack)
		     
	NDC 0078-0315-06</p>
<p>
		     
	   Box of 100 (strips of 10)</p>
<p>
		     
	Unit Dose (<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack of 30)
		     
	NDC 0078-0315-15</p>
<p><span class="Bold">160/25 mg</span> <span class="Bold">Tablet</span> - Brown orange, ovaloid with slightly convex faces debossed NVR on one side and HXH on the other side.</p>
<p>
		     
	Bottles of 90
		     
	NDC 0078-0383-34</p>
<p>
		     
	Bottles of 7,000
		     
	NDC 0078-0383-17</p>
<p>
		     
	Unit Dose (<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack)
		     
	NDC 0078-0383-06</p>
<p>
		     
	   Box of 100 (strips of 10)</p>
<p>
		     
	Unit Dose (<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack of 30)
		     
	NDC 0078-0383-15</p>
<p><span class="Bold">320/12.5</span> <span class="Bold">mg Tablet</span> - Pink, ovaloid with beveled edge, debossed NVR on one side and HIL on the other side.</p>
<p>
		     
	Bottles of 90
		     
	NDC 0078-0471-34</p>
<p>
		     
	Bottles of 3,500
		     
	NDC 0078-0471-11</p>
<p>
		     
	Unit Dose (<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack)
		     
	NDC 0078-0471-06</p>
<p>		     
	Box of 100 (strips of 10)</p>
<p>
		     
	Unit Dose (<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack of 30)
		     
	NDC 0078-0471-15</p>
<p><span class="Bold">320/25 mg</span> <span class="Bold">Tablet</span> - Yellow, ovaloid with beveled edge, debossed NVR on one side and CTI on the other side.</p>
<p>
		     
	Bottles of 90
		     
	NDC 0078-0472-34</p>
<p>
		     
	Bottles of 3,500		     
	NDC 0078-0472-11</p>
<p>
		     
	Unit Dose (<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack)
		     
	NDC 0078-0472-06</p>
<p>
		     
	   Box of 100 (strips of 10)</p>
<p>
		     
	Unit Dose (<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack of 30)
		     
	NDC 0078-0472-15</p>
<p>Store at 25ºC (77ºF); excursions permitted to 15-30ºC (59-86ºF) [see USP Controlled Room Temperature].</p>
<p>Protect from moisture.</p>
<p>Dispense in tight container (USP).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1><span class="Bold">17 PATIENT COUNSELING INFORMATION</span></h1>
<p class="First"><span class="Bold">Information for Patients</span></p>
<p><span class="Bold Italics">Pregnancy</span><span class="Bold Italics">: </span>Female patients of childbearing age should be told that use of drugs like Diovan HCT that act on the renin-angiotensin system during pregnancy can cause serious problems in the fetus and infant including: <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span>, poor development of skull bones, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Discuss other treatment options with female patients planning to become pregnant. Women using Diovan HCT who become pregnant should notify their physician as soon as possible.</p>
<p><span class="Bold Italics">Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span><span class="Bold Italics">: </span>A patient receiving Diovan HCT should be cautioned that <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> can occur, especially during the first days of therapy, and that it should be reported to the prescribing physician. The patients should be told that if <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> occurs, Diovan HCT should be discontinued until the physician has been consulted.</p>
<p>All patients should be cautioned that inadequate fluid intake, excessive perspiration, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> can lead to an excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span>, with the same consequences of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> and possible <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
<p><span class="Bold Italics">Potassium Supplements</span><span class="Bold Italics">: </span>A patient receiving Diovan HCT should be told not to use potassium supplements or salt substitutes containing potassium without consulting the prescribing physician.</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">FDA-Approved Patient Labeling </span></p>
<p><span class="Bold">PATIENT INFORMATION</span></p>
<p><span class="Bold">DIOVAN</span> <span class="Bold">HCT (DYE’</span><span class="Bold">-o</span><span class="Bold">-van HCT)</span></p>
<p><span class="Bold">(valsartan and hydrochlorothiazide) </span></p>
<p><span class="Bold">Tablets</span></p>
<p>Read the Patient Information that comes with DIOVAN HCT before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your condition and treatment. If you have any questions about DIOVAN HCT, ask your doctor or pharmacist.</p>
<a name="id1fd33f7-d78c-459b-86f5-683178cc64e9"></a><table>
<col width="734">
<tbody class="Headless"><tr class="First Last"><td class="Lrule Rrule Toprule">
<span class="Bold">What is the most important information I should know about DIOVAN</span> <span class="Bold">HCT?</span><br><span class="Bold">If you become pregnant, stop taking DIOVAN</span> <span class="Bold">HCT and call your doctor right away. DIOVAN</span> <span class="Bold">HCT can harm an unborn baby causing injury and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </span>If you plan to become pregnant, talk to your doctor about other treatment options to lower your high blood pressure before taking DIOVAN HCT.</td></tr></tbody>
</table>
<p><span class="Bold">What is DIOVAN</span> <span class="Bold">HCT?</span></p>
<p>DIOVAN HCT contains two prescription medicines:</p>
<ol class="Arabic">
<li>valsartan, an angiotensin receptor blocker (ARB)<br>
</li>
<li>hydrochlorothiazide (HCTZ), a water pill (diuretic)</li>
</ol>
<p>DIOVAN HCT may be used to lower high blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>) in adults-</p>
<ul class="Disc">
<li>when one medicine to lower your high blood pressure is not enough<br>
</li>
<li>as the first medicine to lower high blood pressure if your doctor decides you are likely to need more than one medicine.</li>
</ul>
<p>DIOVAN HCT has not been studied in children under 18 years of age.</p>
<p><span class="Bold">Who should not take DIOVAN</span> <span class="Bold">HCT?</span></p>
<p><span class="Bold">Do not take DIOVAN</span> <span class="Bold">HCT if you:</span></p>
<ul class="Disc">
<li>
<span class="Bold">are allergic to any of the ingredients in DIOVAN HCT.</span> See the end of this leaflet for a complete list of ingredients in DIOVAN HCT.<br>
</li>
<li>make less urine due to kidney problems<br>
</li>
<li>are allergic to medicines that contain sulfonamides. </li>
</ul>
<p><span class="Bold">What should I tell my doctor before taking DIOVAN</span> <span class="Bold">HCT?</span></p>
<p><span class="Bold">Tell your doctor about all your medical conditions including if you:</span></p>
<ul class="Disc">
<li>
<span class="Bold">are pregnant or plan to become pregnant.</span> See “What is the most important information I should know about DIOVAN HCT??<br>
</li>
<li>
<span class="Bold">are breast</span><span class="Bold">-feeding.</span> DIOVAN HCT passes into breast milk. You should choose either to take DIOVAN HCT or breast-feed, but not both.<br>
</li>
<li>
<span class="Bold">have liver problems</span><br>
</li>
<li>
<span class="Bold">have kidney problems</span><br>
</li>
<li>
<span class="Bold">have or had <span class="product-label-link" type="condition" conceptid="196456" conceptname="Gallstone">gallstones</span> </span><br>
</li>
<li><span class="Bold">have Lupus</span></li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take</span> including prescription and nonprescription medicines, vitamins and herbal supplements. Some of your other medicines and DIOVAN HCT could affect each other, causing serious side effects. Especially, tell your doctor if you take:</p>
<ul class="Disc">
<li>other medicines for high blood pressure or a heart problem<br>
</li>
<li>water pills (diuretics)<br>
</li>
<li>potassium supplements <br>
</li>
<li>a salt substitute containing potassium<br>
</li>
<li>antidiabetic medicines including insulin<br>
</li>
<li>narcotic <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicines<br>
</li>
<li>sleeping pills<br>
</li>
<li>lithium, a medicine used in some types of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (Eskalith<span class="Sup">®</span>, Lithobid<span class="Sup">®</span>, Lithium Carbonate, Lithium Citrate)<br>
</li>
<li>aspirin or other medicines called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). </li>
</ul>
<p>Ask your doctor if you are not sure if you are taking one of these medicines.</p>
<p>Know the medicines you take. Keep a list of your medicines with you to show to your doctor and pharmacist when a new medicine is prescribed. Talk to your doctor or pharmacist before you start taking any new medicine. Your doctor or pharmacist will know what medicines are safe to take together.</p>
<p><span class="Bold">How should I take DIOVAN</span> <span class="Bold">HCT?</span></p>
<ul class="Disc">
<li>Take DIOVAN HCT exactly as prescribed by your doctor. Your doctor may change your dose if needed.<br>
</li>
<li>Take DIOVAN HCT once each day.<br>
</li>
<li>DIOVAN HCT can be taken with or without food.<br>
</li>
<li>If you miss a dose, take it as soon as you remember. If it is close to your next dose, do not take the missed dose. Just take the next dose at your regular time.<br>
</li>
<li>If you take too much DIOVAN HCT, call your doctor or Poison Control Center, or go to the nearest hospital emergency room.</li>
</ul>
<p><span class="Bold">What should I avoid while taking DIOVAN HCT?</span></p>
<p>You should not take DIOVAN HCT during pregnancy. See “What is the most important information I should know about DIOVAN HCT??</p>
<p><span class="Bold">What are the possible side effects of DIOVAN</span> <span class="Bold">HCT?</span></p>
<p><span class="Bold">DIOVAN</span> <span class="Bold">HCT may cause serious side effects including:</span></p>
<ul class="Disc">
<li>
<span class="Bold">Harm to an unborn baby causing injury and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </span>See “What is the most important information I should know about DIOVAN HCT??<br>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Low blood pressure</span> (<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>).</span> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Low blood pressure</span> is most likely to happen if you:<ul class="Circle">
<li>take water pills <br>
</li>
<li>are on a low salt diet<br>
</li>
<li>get dialysis treatments<br>
</li>
<li>have heart problems<br>
</li>
<li>get sick with <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span><br>
</li>
<li>drink alcohol</li>
</ul>
</li>
</ul>
<p>Lie down if you feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> or dizzy. Call your doctor right away.</p>
<ul class="Disc">
<li>
<span class="Bold">Worsening liver problems</span><span class="Bold">. </span>Liver problems may get worse in people who already have liver problems and take DIOVAN HCT. <br>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span></span><span class="Bold">. </span>People with and without <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> problems or <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> who take DIOVAN HCT may get <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.<br>
</li>
<li>
<span class="Bold">Worsening of Lupus</span><span class="Bold">. </span>Hydrochlorothiazide, one of the medicines in DIOVAN HCT may cause Lupus to become active or worse.<br>
</li>
<li>
<span class="Bold">Fluid and electrolyte (salt) problems</span><span class="Bold">. </span>Tell your doctor about any of the following signs and symptoms of fluid and electrolyte problems:</li>
</ul>
<a name="i3b02f2de-0d7a-4766-824a-b4672b9a1b94"></a><table>
<col width="254">
<col width="247">
<col width="234">
<tbody class="Headless"><tr class="First Last">
<td><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span><br>
</li>
<li>lack of energy (<span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargic</span>)<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></li>
</ul></td>
<td><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span></li>
</ul></td>
<td><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4214612" conceptname="Muscle fatigue">muscle fatigue</span><br>
</li>
<li>very low urine output<br>
</li>
<li>fast heartbeat<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
</ul></td>
</tr></tbody>
</table>
<ul class="Disc">
<li>
<span class="Bold">K</span><span class="Bold">idney problems. </span>Kidney problems may become worse in people that already have kidney disease. Some people will have changes on blood tests for kidney function and may need a lower dose of DIOVAN HCT. Call your doctor if you get <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in your feet, ankles, or hands, or unexplained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. If you have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, your doctor should check your kidney function before prescribing DIOVAN HCT.<br>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span>.</span> Call your doctor right away if you have an unusual <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>. </li>
<li>
<span class="Bold">Eye Problems.</span> One of the medicines in DIOVAN HCT can cause eye problems that may lead to <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span>.  Symptoms of eye problems can happen within hours to weeks of starting DIOVAN HCT.  Tell your doctor right away if you have:<ul class="Disc">
<li>decrease in vision<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span></li>
</ul>
</li>
</ul>
<p>Other side effects were generally mild and brief. They generally have not caused patients to stop taking DIOVAN HCT.</p>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of DIOVAN HCT. For a complete list, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </p>
<p><span class="Bold">How do I store DIOVAN</span> <span class="Bold">HCT?</span></p>
<ul class="Disc">
<li>Store DIOVAN HCT tablets at room temperature between 59<span class="Sup">o</span>F to 86<span class="Sup">o</span>F (15<span class="Sup">o</span>C to 30<span class="Sup">o</span>C).<br>
</li>
<li>Keep DIOVAN HCT in a closed container in a dry place.</li>
</ul>
<p><span class="Bold">Keep DIOVAN</span> <span class="Bold">HCT and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about DIOVAN</span> <span class="Bold">HCT</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use DIOVAN HCT for a condition for which it was not prescribed. Do not give DIOVAN HCT to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This leaflet summarizes the most important information about DIOVAN HCT. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about DIOVAN HCT that is written for health professionals. For more information about DIOVAN HCT, go to <span class="Underline">www.DIOVAN.co</span>m or call 1-866-404-6359.</p>
<p><span class="Bold">What are the ingredients in DIOVAN</span> <span class="Bold">HCT?</span></p>
<p>Active ingredients: Valsartan and hydrochlorothiazide </p>
<p>Inactive ingredients: colloidal silicon dioxide, crospovidone, hydroxypropyl methylcellulose, iron oxides, magnesium stearate, microcrystalline cellulose, polyethylene glycol, talc, and titanium dioxide.</p>
<p><span class="Bold">What is high blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>)?</span> </p>
<p>Blood pressure is the force in your blood vessels when your heart beats and when your heart rests. You have high blood pressure when the force is too much. DIOVAN HCT can help your blood vessels relax and reduce the amount of water in your body so your blood pressure is lower. Medicines that lower blood pressure lower your risk of having a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>. </p>
<p>High blood pressure makes the heart work harder to pump blood throughout the body and causes damage to the blood vessels. If high blood pressure is not treated, it can lead to <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>, and vision problems. </p>
<p>Eskalith<span class="Sup">® </span>and Lithobid<span class="Sup">®</span> are registered trademarks of Noven Pharmaceuticals, Inc.</p>
<p>Distributed by:</p>
<p>Novartis Pharmaceuticals Corporation</p>
<p>East Hanover, New Jersey 07936</p>
<p>© Novartis</p>
<p>T2011-11</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">Package Label – </span><span class="Bold">160</span><span class="Bold"> mg</span><span class="Bold">/25 mg</span></p>
<p>Rx Only
		     
	
		     
	NDC 0078-0383-15</p>
<p>Diovan HCT® </p>
<p>valsartan and hydrochlorothiazide, USP </p>
<p>160 mg/25 mg per tablet</p>
<p>30 tablets</p>
<p>Dosage:  See package insert</p>
<p>Store at 25° C (77° F); excursions permitted to 15-30° C (59-86° F).</p>
<p>Protect from moisture.</p>
<p>Please see accompanying full Prescribing Information.</p>
<p>Keep this and all drugs out of the reach of children.</p>
<br><p><img alt="55289820 Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=85cdc21e-6dbc-4559-9c30-bc93fd21045c&amp;name=55289820.jpg"></p>
<p>PDRx Label<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1></h1>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DIOVAN HCT
                         		
					</strong><br><span class="contentTableReg">valsartan and hydrochlorothiazide tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55289-820(NDC:0078-0383)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">25 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>VALSARTAN</strong> (VALSARTAN) </td>
<td class="formItem">VALSARTAN</td>
<td class="formItem">160 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (Brown orange) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">NVR;HXH</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55289-820-30</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020818</td>
<td class="formItem">03/06/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>PD-Rx Pharmaceuticals, Inc.
							(156893695)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>PD-Rx Pharmaceuticals, Inc. (156893695)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">PD-Rx Pharmaceuticals, Inc.</td>
<td class="formItem"></td>
<td class="formItem">156893695</td>
<td class="formItem">repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>eae9cabc-42e5-4542-a835-7def28cb899e</div>
<div>Set id: 85cdc21e-6dbc-4559-9c30-bc93fd21045c</div>
<div>Version: 8</div>
<div>Effective Time: 20110211</div>
</div>
</div> <div class="DistributorName">PD-Rx Pharmaceuticals, Inc.</div></p>
</body></html>
